Drug Discovery

Discuva secures Innovate UK grant for new antibiotics development

Innovate UK has awarded a £1.5m Biomedical Catalyst early-stage award to drug discovery firm Discuva for the development of novel antibiotics to tackle the issue of multidrug-resistance and life-threatening bacterial infections.

Cue Biopharma raises $26M in funding

Cue Biopharma has announced a total of $26m of invested private capital, led by MDB Capital Group, to develop next-generation biologics to selectively control T Cell activity.

ELC Group partners with PSR Group for advanced drug development

Global life sciences partner ELC Group is collaborating with New Zealand-based research and development firm Pharma Scientific Research (PSR Group) to create highly advanced products for the pharmaceutical market.

Intrexon to buy clinical-stage gene delivery firm GenVec

Intrexon has agreed to acquire clinical-stage company GenVec which has developed the AdenoVerse gene delivery technology.

aTyr Pharma’s Resolaris secures FDA fast track status

The US Food and Drug Administration (FDA) has granted Fast Track designation for aTyr Pharma's Resolaris to treat limb girdle muscular dystrophy 2B (LGMD2B).

Mallinckrodt to pay $100m to settle US charges on drug pricing

Mallinckrodt has agreed to pay $100m to settle the US Federal Trade Commission (FTC) and state charges that it illegally maintained its monopoly of specialty drug used to treat infants.

Horizon Discovery broadens gene editing capabilities

Horizon Discovery Group has expanded its gene editing capabilities through the amendment of a pre-existing license with ERS Genomics to include the full commercial rights for the use of CRISPR edited cell lines for the Good Manufacturing Practice (GMP) manufacturing of biotherapeutics.

Gilead awards more than $22m in grants to support HIV cure research

US biopharmaceutical firm Gilead Sciences has awarded more than $22m in grants to support 12 new HIV cure research projects.

Ipsen to buy Merrimack’s global oncology assets

Ipsen has agreed to acquire global oncology assets from Merrimack Pharmaceuticals, including its key marketed product ONIVYDE (irinotecan liposome injection) for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy, in combination with fluorouracil and leucovorin.